The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients
- PMID: 1380477
- DOI: 10.1002/hep.1840160302
The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients
Abstract
We investigated amino acid heterogeneity in the variable regions of the E2/NS1 viral protein in interferon-responsive and interferon-nonresponsive patients with chronic hepatitis C virus infection. The study assessed whether any particular heterogeneity pattern(s) could be useful in predicting responsiveness to interferon treatment. The nucleic acid sequences of the hepatitis C virus genome were analyzed from six patients with chronic hepatitis treated with an interferon-beta, three of whom did not respond to the therapy and another three who showed remarkable improvement in the serum levels of liver enzymes and hepatitis C virus RNA after 6 mo. The complementary DNA clones propagated from each of the nonresponders showed significant diversity of both nucleotide and amino acid sequence, especially at the hypervariable region 1 within the putative E2/NS1 gene of the virus, suggesting that these patients were infected with a large heterogeneous pool of hepatitis C virus variants. In contrast, the responders showed little or no diversity in the sequence of the complementary DNA clones, suggesting that they were infected with one or a small population of viral genotypes containing significantly less variability in the E2/NS1 hypervariable region 1. These results suggested that a large variable population of hepatitis C virus genotypes is implicated in patients who are nonresponders to interferon treatment. In addition, a significant change in the hepatitis C virus genotype population was observed in nonresponders after interferon treatment. This may reflect a differential viral sensitivity to interferon, selective immune pressure by the host or both.
Similar articles
-
Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients.Hepatology. 1994 Nov;20(5):1121-30. Hepatology. 1994. PMID: 7523271 Clinical Trial.
-
The clinical significance of changes in genetic heterogeneity of the hypervariable region 1 in chronic hepatitis C with interferon therapy.Hepatology. 1996 Nov;24(5):1018-23. doi: 10.1053/jhep.1996.v24.pm0008903369. Hepatology. 1996. PMID: 8903369
-
Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C.J Hepatol. 1995 Dec;23(6):648-53. doi: 10.1016/0168-8278(95)80029-8. J Hepatol. 1995. PMID: 8750162 Clinical Trial.
-
Effects of hepatitis B and hepatitis C virus replication on the actions of interferon.Antiviral Res. 1994 Jul;24(2-3):131-6. doi: 10.1016/0166-3542(94)90061-2. Antiviral Res. 1994. PMID: 7526787 Review.
-
[Problems of interferon therapy in hepatitis C].Nihon Shokakibyo Gakkai Zasshi. 1993 Feb;90(2):85-90. Nihon Shokakibyo Gakkai Zasshi. 1993. PMID: 7681885 Review. Japanese. No abstract available.
Cited by
-
Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy.World J Gastroenterol. 2007 May 7;13(17):2416-26. doi: 10.3748/wjg.v13.i17.2416. World J Gastroenterol. 2007. PMID: 17552024 Free PMC article. Review.
-
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3081-6. doi: 10.1073/pnas.052712599. Proc Natl Acad Sci U S A. 2002. PMID: 11880647 Free PMC article.
-
Usefulness and limitation of phylogenetic analysis for hepatitis C virus core region: application to isolates from Egyptian and Yemeni patients.Arch Virol. 1996;141(6):1101-13. doi: 10.1007/BF01718613. Arch Virol. 1996. PMID: 8712927
-
Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a.J Virol. 2008 Oct;82(19):9417-24. doi: 10.1128/JVI.00896-08. Epub 2008 Jul 30. J Virol. 2008. PMID: 18667493 Free PMC article.
-
Hepatitis C virus envelope proteins bind lactoferrin.J Virol. 1997 Aug;71(8):5997-6002. doi: 10.1128/JVI.71.8.5997-6002.1997. J Virol. 1997. PMID: 9223490 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical